Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population

The aim of this study was to analyze the utility of liver function tests (LFT) and fatty liver index (FLI), a surrogate marker of non-alcoholic fatty liver disease, in the categorization of metabolic phenotypes in a Mediterranean population. A cross-sectional study was performed on a random represen...

Full description

Saved in:
Bibliographic Details
Published in:International journal of environmental research and public health 2020-05, Vol.17 (10), p.3518
Main Authors: Narankiewicz, Dariusz, Ruiz-Nava, Josefina, Buonaiuto, Veronica, Ruiz-Moreno, María Isabel, López-Carmona, María Dolores, Pérez-Belmonte, Luis Miguel, Gómez-Huelgas, Ricardo, Bernal-López, María Rosa
Format: Article
Language:English
Subjects:
Abnormalities
Biobanks
Biomarkers
Blood pressure
Body mass
Body mass index
Body size
Body weight
Cholesterol
Classification
Correlation
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Fatty acids
Fatty liver
Health care
Health care facilities
High density lipoprotein
Hypertension
Hypertriglyceridemia
Liver
Liver diseases
Metabolism
Obesity
Phenotypes
Population
Population studies
Triglycerides
Variables
Variance analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to analyze the utility of liver function tests (LFT) and fatty liver index (FLI), a surrogate marker of non-alcoholic fatty liver disease, in the categorization of metabolic phenotypes in a Mediterranean population. A cross-sectional study was performed on a random representative sample of 2233 adults assigned to a health center in Málaga, Spain. The metabolic phenotypes were determined based on body mass index (BMI) categorization and the presence or absence of two or more cardiometabolic abnormalities (high blood pressure, low high-density lipoprotein (HDL) cholesterol, hypertriglyceridemia, pre-diabetes) or type 2 diabetes. No difference was observed between metabolically healthy and metabolically abnormal phenotypes on LFT. The mean FLI of the population was 41.1 ± 28.6. FLI was significantly higher ( < 0.001) in the metabolically abnormal phenotypes in all BMI categories. The proportion of individuals with pathological FLI (≥60) was significantly higher in the metabolically abnormal overweight and obese phenotypes ( < 0.001). On a multivariate model adjusted for sex, age, and waist circumference, a significant correlation was found between pathological FLI and metabolically abnormal phenotypes in the overweight and obese BMI categories. Area under the curve (AUC) of FLI as a biomarker was 0.76, 0.74, and 0.72 for the metabolically abnormal normal-weight, overweight, and obese groups, respectively. Liver biochemistry is poorly correlated with metabolic phenotypes. Conversely, a good correlation between FLI, as a marker of non-alcoholic fatty liver disease (NAFLD), and metabolically abnormal phenotypes in all BMI ranges was found. Our study suggests that FLI may be a useful marker for characterizing metabolically abnormal phenotypes in individuals who are overweight or obese.
ISSN:1660-4601
1661-7827
1660-4601
DOI:10.3390/ijerph17103518